{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:05:54Z","timestamp":1789560354775,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","award":["P50 MH119467"],"award-info":[{"award-number":["P50 MH119467"]}],"id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","award":["R37 MH068376"],"award-info":[{"award-number":["R37 MH068376"]}],"id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00479-3","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:23:48Z","timestamp":1789032228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization, automation and validation of\u00a0NOP receptor\u00a0PET radiopharmaceutical, [11C]NOP-1A for human use"],"prefix":"10.1186","volume":"11","author":[{"given":"Daniel L.","family":"Yokell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-5746","authenticated-orcid":false,"given":"Maeva","family":"Dhaynaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Neelamegam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Normandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Pizzagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"El Fakhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"6","key":"479_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.biopsych.2019.09.013","volume":"87","author":"M Flanigan","year":"2020","unstructured":"Flanigan M, Tollefson S, Himes ML, Jordan R, Roach K, Stoughton C, et al. Acute elevations in cortisol increase the in vivo binding of [11C]NOP-1A to nociceptin receptors: a novel imaging paradigm to study the interaction between stress- and antistress-regulating neuropeptides. Biol Psychiatry. 2020;87(6):570\u20136.","journal-title":"Biol Psychiatry"},{"key":"479_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroimage.2013.10.068","volume":"87","author":"TG Lohith","year":"2014","unstructured":"Lohith TG, Zoghbi SS, Morse CL, Araneta MDF, Barth VN, Goebl NA, et al. Retest imaging of [11C]NOP-1A binding to nociceptin\/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. Neuroimage. 2014;87:89\u201395.","journal-title":"Neuroimage"},{"issue":"3","key":"479_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2967\/jnumed.111.097162","volume":"53","author":"TG Lohith","year":"2012","unstructured":"Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, et al. Brain and whole-body imaging of nociceptin\/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A. J Nucl Med. 2012;53(3):385\u201392.","journal-title":"J Nucl Med"},{"issue":"10","key":"479_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.biopsych.2017.05.019","volume":"84","author":"R Narendran","year":"2018","unstructured":"Narendran R, Ciccocioppo R, Lopresti B, Paris J, Himes ML, Mason NS. Nociceptin receptors in alcohol use disorders: a positron emission tomography study using [11C]NOP-1A. Biol Psychiatry. 2018;84(10):708\u201314.","journal-title":"Biol Psychiatry"},{"issue":"12","key":"479_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.biopsych.2019.02.017","volume":"85","author":"R Narendran","year":"2019","unstructured":"Narendran R, Tollefson S, Fasenmyer K, Paris J, Himes ML, Lopresti B, et al. Decreased nociceptin receptors are related to resilience and recovery in college women who have experienced sexual violence: therapeutic implications for posttraumatic stress disorder. Biol Psychiatry. 2019a;85(12):1056\u201364.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"479_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1176\/appi.ajp.2019.18081007","volume":"176","author":"R Narendran","year":"2019","unstructured":"Narendran R, Tollefson S, Himes ML, Paris J, Lopresti B, Ciccocioppo R, et al. Nociceptin receptors upregulated in cocaine use disorder: a positron emission tomography imaging study using [11C]NOP-1A. Am J Psychiatry. 2019b;176(6):468\u201376.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"479_CR7","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1021\/jm101487v","volume":"54","author":"VW Pike","year":"2011","unstructured":"Pike VW, Rash KS, Chen Z, Pedregal C, Statnick MA, Kimura Y, et al. Synthesis and evaluation of radioligands for imaging brain nociceptin\/orphanin FQ peptide (NOP) receptors with positron emission tomography. J Med Chem. 2011;54(8):2687\u2013700.","journal-title":"J Med Chem"},{"issue":"23","key":"479_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312956","volume":"22","author":"M Ubaldi","year":"2021","unstructured":"Ubaldi M, Cannella N, Borruto AM, Petrella M, Micioni Di Bonaventura MV, Soverchia L, et al. Role of nociceptin\/orphanin FQ-NOP receptor system in the regulation of stress-related disorders. Int J Mol Sci. 2021;22(23):12956.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"479_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pharmthera.2013.10.011","volume":"141","author":"JM Witkin","year":"2014","unstructured":"Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, et al. The biology of nociceptin\/orphanin FQ (N\/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther. 2014;141(3):283\u201399.","journal-title":"Pharmacol Ther"},{"issue":"15","key":"479_CR10","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1021\/acs.jmedchem.5b01499","volume":"59","author":"NT Zaveri","year":"2016","unstructured":"Zaveri NT. Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility: miniperspective. J Med Chem. 2016;59(15):7011\u201328.","journal-title":"J Med Chem"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00479-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00479-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:28:33Z","timestamp":1789558113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00479-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00479-3","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No human subjects or animal experiments were directly involved in this methodological radiochemistry and validation study. The work focused on the development, optimization, automation, and validation of the radiopharmaceutical\u00a0[\n                      11\n                      C]NOP-1A for human use under current Good Manufacturing Practice (cGMP) conditions and in accordance with United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP) regulations. The synthesis method was accepted by the FDA under IND 140,471.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Over the past 3\u00a0years, DP has received consulting fees from Abbvie, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, N1 Bio Cor, Syntropic Medical, Tap Sciences, and Xenon Pharmaceuticals; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) as well as Alkermes; he has received research funding from the BIRD Foundation, Brain and Behavior Research Foundation, Circular Genomics, Dana Foundation, Millennium Pharmaceuticals, National Institute Mental Health, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, GLX Analytix, Neumora Therapeutics, and Neuroscience Software. All other authors report no financial relationships with commercial interests. Dr. Yokell is currently an employee of Telix Pharmaceuticals (US) and Ramesh Neelamegam of PharmaLogic (US).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"65"}}